Alpha1-Antitrypsin Deficiency research hub
4 indexed studies · 3 currently recruiting
- recruitingPHASE3
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
This study investigates if a new drug called fazirsiran can help reduce liver scarring in people with Alpha-1 Antitrypsin Deficiency. Researchers also want to see if it slows liver disease, understand how it works in the body, and check for side effects.
United States · Australia · Austria - recruiting
A Study in Adults to Learn About Inherited Alpha-1 Antitrypsin Deficiency (AATD) and AATD Related Liver Problems
This study aims to understand how liver problems develop in adults with Alpha-1 Antitrypsin Deficiency (AATD) when left untreated. Researchers will follow participants for five years to learn about the condition's progression, diagnosis, and how it affects lung health.
United States · Germany - active not recruitingPHASE3
An Extension Study to Learn About the Long-Term Safety of Fazirsiran and if Fazirsiran Can Help People With Alpha-1 Antitrypsin Liver Disease
This study looks at how safe a medicine called fazirsiran is for people with liver disease caused by a condition called Alpha-1 Antitrypsin Deficiency. It's for those who have been in previous fazirsiran studies and will check if the medicine helps their liver over a long time.
United States · Austria · Germany - recruitingPHASE3
Study to Learn About the Safety of Fazirsiran and if it Can Help People With Alpha-1 Antitrypsin Liver Disease With Mild Liver Scarring (Fibrosis)
This study looks at a new medicine, fazirsiran, for people with a genetic liver condition called Alpha-1 Antitrypsin Deficiency, who have early liver scarring. It aims to see if the medicine is safe, well-tolerated, and can help reduce the abnormal protein buildup that causes liver damage.
United States · Austria · Belgium